Somatic mutation profiles were examined in 126 AML patients from the TCGA-LAML cohort, of whom 91 (72.22%) harbored at least one mutation in the top ten most frequently mutated genes (DNMT3A, FLT3, NPM1, TET2, CEBPA, IDH1, IDH2, RUNX1, WT1, and TP53) (Figs 6A and 6B). This evidence concerns the gene IDH2 and acute myeloid leukemia.